Propafenone

Česká verzia

Authors: Vítovec J.; Špinarová L.; Špinar J.
Authors place of work: I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
Published in the journal: Kardiol Rev Int Med 2019, 21(4): 221-222

Summary

Propafenone hydrochloride is a potent antiarrhythmic agent effective in both supraventricular and ventricular arrhythmias. According to the Vaughan Williams classification, it belongs to class Ic antiarrhythmic medication, but with concurrent betareceptor antagonist activity. Propafenone is used in oral and intravenous form for the restoration of sinus rhythm in atrial fibrillation, orally for the prevention of recurrences of atrial fibrillation and the maintenance of sinus rhythm or for the suppression of ventricular ectopy. Propafenone is generally indicated in patients without structural heart disease and is unsuitable for heart failure.

Keywords:

atrial fibrillation – propafenone – antiarrhythmic drug – ventricular ectopy – structural heart disease

Zdroje

1. Lefflerová K. Propafenon. Remedia 2017; 27: 494–497.

2. Stoschitzky K, Stoschitzky G, Lercher P et al. Propafenone shows class Ic and class II antiarrhythmics effects. Europace 2016; 18(4): 568–571. doi: 10.1093/ europace/ euv195.

3. Novák M, Lábrová R, Nováková Z et al. Antiarytmika: 125–158. In: Vítovec J, Špinar J, Špinarová L a kol. Farmakoterapie kardiovaskulárních onemocnění. 3. vyd. Praha: Grada 2017.

4. Bytešník J. Antiarytmická farmakologická léčba fibrilace síní. Remedia 2011; 21(2): 140–146.

5. Brugada J, Katritsis DG, Arbelo E et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. Eur Heart J 2019: pii: ehz467. doi: 10.1093/ eurheartj/ ehz467.

6. Čihák R, Haman L, Táborský M. Doporučené postupy ESC 2016 pro léčbu fibrilace síní formulované ve spolupráci s EACTS. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2016; 58(6): 636–683. doi: 10.1016/ j.crvasa.2016.11.005.